Clinical Report: FDA Veteran Shares Insights on Trial Design and Endpoints

Overview

Dr. Wiley A. Chambers discusses the regulatory requirements for clinical trials in ophthalmology, emphasizing the need for confirmatory evidence often necessitating two phase 3 trials. He highlights the importance of visual function endpoints in trials for intermediate age-related macular degeneration (AMD).

Background

Understanding the regulatory landscape for clinical trials is crucial for the development of new therapies, particularly in ophthalmology where safety and efficacy are paramount. The FDA's expectations for trial design and endpoints directly influence the approval process for retinal therapies. As the complexity of clinical trials increases, clarity on these aspects becomes essential for successful drug development.

Data Highlights

No numerical data available in the source material.

Key Findings

• The FDA requires at least one adequate and well-controlled trial for drug approval, but two trials are often recommended for confirmatory evidence.
• Endpoints for intermediate AMD trials focus on improvement in visual function, which is critical for patient quality of life.
• Visual acuity is a key measure in assessing treatment efficacy, as it relates to patients' ability to live independently.
• Recent FDA guidance emphasizes the importance of early engagement on endpoint selection for ophthalmology programs.
• Single pivotal trials can support approval but must be large and statistically robust.

Clinical Implications

Clinicians should be aware of the regulatory expectations when designing trials for retinal therapies, particularly the emphasis on visual function as a primary endpoint. Planning for two phase 3 trials may enhance the likelihood of obtaining regulatory approval by providing robust confirmatory evidence.

Conclusion

The insights shared by Dr. Chambers underscore the critical role of trial design and endpoints in the successful development of therapies for retinal diseases. Adhering to FDA guidelines will be essential for advancing clinical research in this field.

Related Resources & Content

1. The ASCO Post, 2015 -- Smarter Trial Design Saves Money and Produces Better Drugs
2. the medicine maker, 2026 -- Rethinking Progress in Clinical Trials
3. Bone Marrow Transplantation, 2021 -- Designing Clinical Trials: Key Endpoints and Outcome Interpretation
4. FDA -- Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments
5. The ASCO Post — National Cancer Policy Summit: Setting Priorities for the Next 3 Years
6. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments | FDA
7. Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials - PubMed
8. ----------------------- WARNINGS AND PRECAUTIONS------------------------ • Endophthalmitis and Retinal Detachments (5.1) • Retinal Vasculitis and/or Retinal Vascular Occlusion (5.2) • Neovascular AMD (5.3) | | |